Skip to content

THE POWER OF XELPROS

Innovative delivery of latanoprost in the first and only BAK-free formulation for the treatment of open-angle glaucoma or ocular hypertension1,2

THE PROVEN IOP-LOWERING POWER OF XELPROS1,2,a

In clinical trials, XELPROS demonstrated significant reductions in intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension1

  • The mean IOP-lowering effect was 6-8 mmHg in patients with mean baseline IOP of 23-26 mmHg1
  • XELPROS showed IOP-lowering power throughout the day similar to Xalatan®2,a

XELPROS DEMONSTRATED SAFETY IN CLINICAL TRIALS1

The most common ocular adverse reactions in clinical trials (incidence ≥5%) for XELPROS were1:

  • Eye pain/stinging
  • Ocular hyperemia
  • Conjunctival hyperemia
  • Eye discharge
  • Growth of eyelashes
  • Eyelash thickening

The majority of ocular adverse
events were considered
mild (78.4%) and <1% of
patients discontinued due to
ocular side effects1,2

DOSING, STORAGE, AND ADMINISTRATION

One drop icon

One drop in the affected eye(s) once daily in the evening1

Multidose icon

Supplied in multidose bottle for easy administration1

Thermometer icon

Can be stored in refrigerator or at room temperature (36ºF to 77ºF [2ºC to 25ºC])1

Contact lens icon

Contact lenses should be removed prior to administration of XELPROS and may be reinserted 15 minutes following administration1

There is no generic equivalent for XELPROS. Be sure to write “brand medically necessary” when prescribing to your patients3

aStudy design: The efficacy and safety of XELPROS were assessed in 2 randomized, active-controlled (vs Xalatan) clinical trials in patients with open-angle glaucoma or ocular hypertension. Study 1 included 104 patients (53 received XELPROS) with IOP measured in the morning and evening over 4 weeks. Study 2 included 578 patients (289 received XELPROS) with IOP measured at 8:00 am, 10:00 am, and 4:00 pm over 12 weeks. XELPROS was dosed once daily in the evening in both trials.2

INDICATIONS AND USAGE

XELPROS (latanoprost ophthalmic emulsion) 0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XELPROS is contraindicated in patients with a known hypersensitivity to latanoprost, or any other ingredients in this product.

WARNINGS AND PRECAUTIONS

Pigmentation: XELPROS may cause changes to pigmented tissues. The most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as XELPROS is administered. After discontinuation of XELPROS, iris pigmentation is likely to be permanent. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known.

Eyelash Changes: XELPROS may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, pigmentation, and number of lashes. The changes are usually reversible upon discontinuation of treatment.

Intraocular Inflammation: XELPROS should be used with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation.

Macular Edema: XELPROS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Herpetic Keratitis: XELPROS should be used with caution in patients with a history of herpetic keratitis. XELPROS should be avoided in cases of active herpes simplex keratitis because inflammation may be exacerbated.

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

Use with Contact Lenses: Contact lenses should be removed prior to administration of XELPROS and may be reinserted 15 minutes following administration.

ADVERSE REACTIONS

The most common ocular adverse reactions in clinical trials (incidence ≥5%) for XELPROS were eye pain/stinging, ocular hyperemia, conjunctival hyperemia, eye discharge, growth of eyelashes, and eyelash thickening.

DRUG INTERACTIONS

Precipitation may occur if drugs containing thimerosal are used concomitantly with XELPROS. If such drugs are used, they should be administered at least 5 minutes apart.

Please see the Full Prescribing Information.

BAK=benzalkonium chloride.

References: 1. XELPROS [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; 2018. 2. Data on file. Cranbury, NJ: Sun Pharmaceutical Industries, Inc. 3. FDA.gov. Drugs@FDA: FDA approved drug products. XELPROS. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206185. Accessed October 10, 2018.